The TREM2 agonistic antibody AL002 in early Alzheimer’s disease: a phase 2 randomized trial

Journal:

Nature Medicine

Published:

2026-03-05

DOI:

10.1038/s41591-026-04273-1

Affiliations:

7

Authors:

21

Go to article

Institutions	Authors	Share
Alector, United States of America (USA)	16.000000 16.000000	0.76
National Hospital for Neurology and Neurosurgery (NHNN), UCLH, United Kingdom (UK)	1.000000	0.05
Alpha Biometrics Consulting, United States of America (USA)	1.000000	0.05
California Advanced Imaging Medical Associates, Inc. (CAIMA), United States of America (USA)	1.000000	0.05
Brown University, United States of America (USA)	1.000000	0.05
Global R&D Partners, LLC, United States of America (USA)	0.500000	0.02
University of California, San Diego (UC San Diego), United States of America (USA)	0.500000	0.02

Interested in Neurosciences?